Pancreatic Cancer Research

ResearcherNankai UniversityActive in the last 2 years

Quanli Han

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7389-934X; OpenAlex author ID A5100717226. Sources: OpenAlex.

Their work

Papers
14 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers

Papers 14

  1. First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metast… Co-author DOI 10.1038/s41392-025-02441-2↗
  2. Development and Validation of the Predictive and Prognostic ChemoResist Signature in Resected Pancreatic Ductal Adenocarcinoma: Multicohort Study. First author DOI 10.1097/sla.0000000000006610↗
  3. Association of lung immune prognostic index with overall survival in pancreatic ductal adenocarcinoma patients treated using chemotherapy. Co-author DOI 10.7150/ijms.102404↗
  4. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospect… Co-author DOI 10.1186/s12967-024-04989-z↗
  5. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications. Co-author DOI 10.1002/cam4.5871↗
  6. Gene signature developed for predicting early relapse and survival in early-stage pancreatic cancer. Co-author DOI 10.1093/bjsopen/zrad031↗
  7. S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study. First author DOI 10.3389/fonc.2022.865404↗
  8. Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma. Co-author DOI 10.3389/fonc.2022.926260↗
  9. Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer. Co-author DOI 10.1186/s12885-021-08943-w↗
  10. Identification of DNA methylation-driven genes and construction of a nomogram to predict overall survival in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-215080/v1↗
  11. Preoperative CA19-9 levels predict disease-free survival and overall survival in pancreatic adenocarcinoma patients after resection. Co-author DOI 10.21037/tcr.2019.04.24↗
  12. Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based … Co-author DOI 10.1111/jcpt.12655↗
  13. Survival of patients with advanced pancreatic cancer after iodine125 seeds implantation brachytherapy: A meta-analysis. Co-author DOI 10.1097/md.0000000000005719↗
  14. Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. Co-author DOI 10.18632/oncotarget.21359↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guanghai Dai · 12 shared papers, 2017–2025 · strength 1.99
  2. Guochao Deng · 5 shared papers, 2019–2025 · strength 0.93
  3. Lei Huang · 4 shared papers, 2022–2025 · strength 0.84
  4. Shasha Guan · 5 shared papers, 2019–2024 · strength 0.80
  5. Yan Xia Shi · 4 shared papers, 2017–2025 · strength 0.69
  6. Liangchao Zhao · 2 shared papers, 2023–2025 · strength 0.47
  7. Nan Zhang · 1 shared paper, 2025 · strength 0.33
  8. Yan Shi · 1 shared paper, 2024 · strength 0.22
  9. Rong Liu · 2 shared papers, 2017–2023 · strength 0.22
  10. Guanghai Dai · 1 shared paper, 2025 · strength 0.20
  11. Ru Jia · 1 shared paper, 2025 · strength 0.20
  12. Mengjiao Fan · 1 shared paper, 2025 · strength 0.20
  13. Jie Li · 1 shared paper, 2022 · strength 0.15
  14. Shuang Si · 1 shared paper, 2023 · strength 0.15
  15. Zhuzeng Yin · 1 shared paper, 2023 · strength 0.15
  16. Zhiming Zhao · 1 shared paper, 2023 · strength 0.15
  17. Wei Li · 1 shared paper, 2023 · strength 0.15
  18. Qu Liu · 1 shared paper, 2023 · strength 0.15
  19. T. T. Qu · 1 shared paper, 2021 · strength 0.14
  20. G. C. Deng · 1 shared paper, 2021 · strength 0.14
  21. Yang Chen · 1 shared paper, 2019 · strength 0.11
  22. Jie Li · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.